SOLAR-1: Alpelisib + Fulvestrant in PIK3CA-Mutated HR+/HER2− Advanced Breast Cancer — Mobile Quick Reference

Save for clinic

📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications

🎯 Clinical Bottom Line

Adding alpelisib to fulvestrant nearly doubles PFS in PIK3CA-mutated HR+/HER2− advanced breast cancer after prior aromatase inhibitor therapy. No benefit in PIK3CA wild-type tumors — mutation testing is mandatory. Hyperglycemia and rash are the dominant toxicities; proactive management is essential to keep patients on therapy.

Key Result: Median PFS (PIK3CA-mutated cohort) — 11.0 vs 5.7 months, HR 0.65 (95% CI 0.50–0.85; P<0.001)

Safety Signal: Hyperglycemia any grade 63.7%, grade 3: 32.7%, grade 4: 3.9%. Rash (grouped) any grade 53.9%, grade ≥3: 20.1%. Discontinuation due to AE: 25.0%.

✅ Patient Eligibility

Must Have:

• HR-positive, HER2-negative advanced breast cancer
• PIK3CA mutation confirmed by FDA-approved test
• Previous endocrine therapy (AI-based)
• ECOG PS 0–1
• Postmenopausal or male

Cannot Have:

• Prior chemotherapy for advanced disease
• Prior fulvestrant
• Prior PI3K/AKT/mTOR inhibitor
• Uncontrolled diabetes (relative; requires optimization before start)

💊 Dosing Quick Guide

Experimental Regimen

Alpelisib: 300 mg PO daily with food (continuous) Fulvestrant: 500 mg IM on days 1, 15 of cycle 1, then day 1 of 28-day cycles Duration: Until progression or intolerable toxicity

Control Regimen

Placebo + Fulvestrant 500 mg IM (same schedule)

Key Dose Modifications [2]

• Dose reduction levels: 300 mg → 250 mg → 200 mg → discontinue
• Hyperglycemia: Hold if FPG >250 mg/dL; discontinue if confirmed FPG >500 mg/dL
• Rash grade ≥3: Hold; may resume at same or reduced dose after improvement

Key Monitoring [2]

• FPG at least every 2 weeks × 2 months, then monthly
• HbA1c at baseline
• Consider metformin prophylaxis
• Skin assessment first 2 weeks

Mechanism: Alpelisib is a selective PI3Kα inhibitor that blocks constitutively activated PI3K signaling in tumors with PIK3CA gain-of-function mutations [2].

⚠️ Safety Snapshot

⚠️ Hyperglycemia (grouped term): Any grade 65.8%, Grade ≥3 38.0% — vs 10.5% / 0.7% placebo

⚠️ Rash (grouped term): Any grade 53.9%, Grade ≥3 20.1% — vs 8.4% / 0.3% placebo

Key safety metrics:

• Serious AEs: 99 (34.9%) vs 48 (16.7%)
• Discontinuation due to AE: 71 (25.0%) vs 12 (4.2%)
• Dose reductions: 108 (63.9%) vs 15 (8.8%)*
• Dose interruptions: 125 (74.0%) vs 55 (32.2%)*
• Deaths on trial: 7 (2.5%) vs 12 (4.2%)

*PIK3CA-mutated cohort only

📊 Key Numbers

Median follow-up: 20.0 months (PIK3CA-mutated cohort)

🔬 Key Comparator Context

Cross-trial comparisons are limited by differences in populations, designs, and endpoints.

🔍 Subgroups to Watch

Prior CDK4/6 inhibitor (n=20): HR 0.48 (0.17–1.36) — favorable point estimate but very wide CI; only 5.9% of cohort had prior CDK4/6i exposure

Second line in advanced disease: HR 0.61 (0.42–0.89) — numerically better than first line (HR 0.71)

PIK3CA H1047X (n=193): HR 0.68 (0.48–0.95) — most common mutation, consistent benefit

Non-PIK3CA-mutated cohort: HR 0.85 (0.58–1.25) — proof-of-concept NOT met; no benefit without mutation

Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.

📋 Regulatory Status

⚠️ Verify current regulatory status before prescribing.

NCCN: Preferred regimen option for HR+/HER2− metastatic BC with PIK3CA mutation, post-endocrine therapy [3]

⚡ Grey Zones

• Only 5.9% had prior CDK4/6 inhibitor — unclear applicability to current post-CDK4/6i setting
• Overall survival not reported in this publication
• 25% discontinuation rate and 64% dose reduction rate raise real-world effectiveness concerns
• No head-to-head comparison with capivasertib–fulvestrant for PI3K pathway-altered tumors
• Liquid biopsy vs tissue testing concordance not fully characterized in this trial

📖 Full Analysis

Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.

References

1. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904
2. Piqray (alpelisib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. Accessed March 2026.
4. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve). Lancet Oncol. 2021;22(4):489-498.
5. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070.
6. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo (PALOMA-3). Lancet Oncol. 2016;17(4):425-439.